
First patient dosed with new Tourette syndrome therapy
The first patient has been dosed in a trial for an investigational Tourette syndrome therapy. Biopharmaceutical company Emalex Biosciences announced that the first patient was dosed in its expanded access programme for ecopipam, an investigational first-in-class D1 receptor antagonist in development for the treatment of Tourette syndrome. … Read More














